ReP USP - Resultado da busca

Artigo de periodico
Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib (2014)
Fonseca, Leonardo Gomes da; Barroso-Sousa, Romulado; Bento, Afonso da Silva Alves; Blanco, Bruna Paccola; Valente, Gabriel Luis; Pfiffer, Tulio Eduardo Flesch; Hoff, Paulo Marcelo; Sabbaga, Jorge
Source: Medical Oncology. Unidade: FM
Subjects: NEOPLASIAS HEPÁTICAS (TERAPIA), TAXA DE SOBREVIVÊNCIA, PROGNÓSTICO, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FONSECA, Leonardo Gomes da et al. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Medical Oncology, v. 31, p. 1-6, 2014Tradução . . Disponível em: https://doi.org/10.1007/s12032-014-0264-5. Acesso em: 02 jun. 2024.
APA
Fonseca, L. G. da, Barroso-Sousa, R., Bento, A. da S. A., Blanco, B. P., Valente, G. L., Pfiffer, T. E. F., et al. (2014). Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Medical Oncology, 31, 1-6. doi:10.1007/s12032-014-0264-5
NLM
Fonseca LG da, Barroso-Sousa R, Bento A da SA, Blanco BP, Valente GL, Pfiffer TEF, Hoff PM, Sabbaga J. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib [Internet]. Medical Oncology. 2014 ; 31 1-6.[citado 2024 jun. 02 ] Available from: https://doi.org/10.1007/s12032-014-0264-5
Vancouver
Fonseca LG da, Barroso-Sousa R, Bento A da SA, Blanco BP, Valente GL, Pfiffer TEF, Hoff PM, Sabbaga J. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib [Internet]. Medical Oncology. 2014 ; 31 1-6.[citado 2024 jun. 02 ] Available from: https://doi.org/10.1007/s12032-014-0264-5
Artigo de periodico
Should extragonadal germ cell tumors be included in studies of families with testicular germ cell tumors? (2013)
Guindalini, Rodrigo Santa Cruz; Oliveira, Edite Paulo de; Silvino, Marina Cavalcanto Moroja; Hoff, Paulo Marcelo; Garicochea , Bernardo
Source: Hereditary Cancer in Clinical Practice. Unidade: FM
Subjects: GENÉTICA MÉDICA, FATORES DE RISCO, BIÓPSIA, DOENÇAS HEREDITÁRIAS, NEOPLASIAS TESTICULARES (CIRURGIA), TESTÍCULO (ULTRASONOGRAFIA)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GUINDALINI, Rodrigo Santa Cruz et al. Should extragonadal germ cell tumors be included in studies of families with testicular germ cell tumors?. Hereditary Cancer in Clinical Practice, v. 11, n. 1, p. (online), 2013Tradução . . Disponível em: https://doi.org/10.1186/1897-4287-11-1. Acesso em: 02 jun. 2024.
APA
Guindalini, R. S. C., Oliveira, E. P. de, Silvino, M. C. M., Hoff, P. M., & Garicochea , B. (2013). Should extragonadal germ cell tumors be included in studies of families with testicular germ cell tumors? Hereditary Cancer in Clinical Practice, 11( 1), (online). doi:10.1186/1897-4287-11-1
NLM
Guindalini RSC, Oliveira EP de, Silvino MCM, Hoff PM, Garicochea B. Should extragonadal germ cell tumors be included in studies of families with testicular germ cell tumors? [Internet]. Hereditary Cancer in Clinical Practice. 2013 ; 11( 1): (online).[citado 2024 jun. 02 ] Available from: https://doi.org/10.1186/1897-4287-11-1
Vancouver
Guindalini RSC, Oliveira EP de, Silvino MCM, Hoff PM, Garicochea B. Should extragonadal germ cell tumors be included in studies of families with testicular germ cell tumors? [Internet]. Hereditary Cancer in Clinical Practice. 2013 ; 11( 1): (online).[citado 2024 jun. 02 ] Available from: https://doi.org/10.1186/1897-4287-11-1
Artigo de periodico
Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy (2013)
Jürgensmeier, J. M.; Schmoll, H-J; Robertson, J. D.; Brooks, L.; Taboada, M.; Morgan, S. R.; Wilson, D.; Hoff, P. M.
Source: British Journal of Cancer. Unidade: FM
Subjects: BIOMARCADORES, NEOPLASIAS (PREVENÇÃO E CONTROLE)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
JÜRGENSMEIER, J. M. et al. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. British Journal of Cancer, v. 108, n. 6, p. 1316-1323, 2013Tradução . . Disponível em: https://doi.org/10.1038/bjc.2013.79. Acesso em: 02 jun. 2024.
APA
Jürgensmeier, J. M., Schmoll, H. -J., Robertson, J. D., Brooks, L., Taboada, M., Morgan, S. R., et al. (2013). Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. British Journal of Cancer, 108( 6), 1316-1323. doi:10.1038/bjc.2013.79
NLM
Jürgensmeier JM, Schmoll H-J, Robertson JD, Brooks L, Taboada M, Morgan SR, Wilson D, Hoff PM. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy [Internet]. British Journal of Cancer. 2013 ; 108( 6): 1316-1323.[citado 2024 jun. 02 ] Available from: https://doi.org/10.1038/bjc.2013.79
Vancouver
Jürgensmeier JM, Schmoll H-J, Robertson JD, Brooks L, Taboada M, Morgan SR, Wilson D, Hoff PM. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy [Internet]. British Journal of Cancer. 2013 ; 108( 6): 1316-1323.[citado 2024 jun. 02 ] Available from: https://doi.org/10.1038/bjc.2013.79
Trabalho de evento-resumo periodico
Erlotinib in metastatic pulmonary adenocarcinomas harbouring EGFR activating mutations, in Sao Paulo - Brazil (2013)
Caires-Lima, Rafael; Protasio, Bruno M.; Takahashi, Tiago K.; Mak, Milena P.; Nakazato, Denyei; Mesquita, Cristiane S.; Takagaki, Teresa Y.; Soares, Iberê C.; Mello, Evandro S.; Hoff, Paulo M.; Alves, Venâncio A.; Castro Jr., Gilberto
Source: Journal of thoracic oncology. Conference titles: World Conference on Lung Cancer. Unidade: FM
Subjects: NEOPLASIAS PULMONARES, POLIMORFISMO, ADENOCARCINOMA, MUTAÇÃO, METÁSTASE NEOPLÁSICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CAIRES-LIMA, Rafael et al. Erlotinib in metastatic pulmonary adenocarcinomas harbouring EGFR activating mutations, in Sao Paulo - Brazil. Journal of thoracic oncology. [S.l.]: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 02 jun. 2024. , 2013
APA
Caires-Lima, R., Protasio, B. M., Takahashi, T. K., Mak, M. P., Nakazato, D., Mesquita, C. S., et al. (2013). Erlotinib in metastatic pulmonary adenocarcinomas harbouring EGFR activating mutations, in Sao Paulo - Brazil. Journal of thoracic oncology. Faculdade de Medicina, Universidade de São Paulo.
NLM
Caires-Lima R, Protasio BM, Takahashi TK, Mak MP, Nakazato D, Mesquita CS, Takagaki TY, Soares IC, Mello ES, Hoff PM, Alves VA, Castro Jr. G. Erlotinib in metastatic pulmonary adenocarcinomas harbouring EGFR activating mutations, in Sao Paulo - Brazil. Journal of thoracic oncology. 2013 ; 8 S892.[citado 2024 jun. 02 ]
Vancouver
Caires-Lima R, Protasio BM, Takahashi TK, Mak MP, Nakazato D, Mesquita CS, Takagaki TY, Soares IC, Mello ES, Hoff PM, Alves VA, Castro Jr. G. Erlotinib in metastatic pulmonary adenocarcinomas harbouring EGFR activating mutations, in Sao Paulo - Brazil. Journal of thoracic oncology. 2013 ; 8 S892.[citado 2024 jun. 02 ]
Artigo de periodico
Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy (2013)
Spencer, S. K. M.; Pommier, A. J. C.; Morgan, S. R.; Barry, S. T.; Robertson, J. D.; Hoff, P. M.; Jürgensmeier, J. M.
Source: British Journal of Cancer. Unidade: FM
Subjects: BIOMARCADORES, NEOPLASIAS COLORRETAIS (TERAPIA), ANTINEOPLÁSICOS (APLICAÇÕES TERAPÊUTICAS), PROGNÓSTICO, METÁSTASE NEOPLÁSICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SPENCER, S. K. M. et al. Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy. British Journal of Cancer, v. 109, n. 11, p. 2765-2773, 2013Tradução . . Disponível em: https://doi.org/10.1038/bjc.2013.649. Acesso em: 02 jun. 2024.
APA
Spencer, S. K. M., Pommier, A. J. C., Morgan, S. R., Barry, S. T., Robertson, J. D., Hoff, P. M., & Jürgensmeier, J. M. (2013). Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy. British Journal of Cancer, 109( 11), 2765-2773. doi:10.1038/bjc.2013.649
NLM
Spencer SKM, Pommier AJC, Morgan SR, Barry ST, Robertson JD, Hoff PM, Jürgensmeier JM. Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy [Internet]. British Journal of Cancer. 2013 ; 109( 11): 2765-2773.[citado 2024 jun. 02 ] Available from: https://doi.org/10.1038/bjc.2013.649
Vancouver
Spencer SKM, Pommier AJC, Morgan SR, Barry ST, Robertson JD, Hoff PM, Jürgensmeier JM. Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy [Internet]. British Journal of Cancer. 2013 ; 109( 11): 2765-2773.[citado 2024 jun. 02 ] Available from: https://doi.org/10.1038/bjc.2013.649
Trabalho de evento-resumo periodico
Risk factors for severe complications during febrile neutropenic episodes in patients with solid tumors: should it be different in elderly? (2013)
Martins, R.; Cecotti, H. C.; Pierrotti, L. C.; Abdala, E.; Hoff, Paulo Marcelo Gehm; Castro, G.
Source: European Journal of Cancer. Conference titles: European Cancer Congress 2013 Abstract Book. Unidade: FM
Subjects: NEOPLASIAS (RADIOTERAPIA), FATORES DE RISCO, FEBRE (ETIOLOGIA), ANTIBIÓTICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MARTINS, R. et al. Risk factors for severe complications during febrile neutropenic episodes in patients with solid tumors: should it be different in elderly?. European Journal of Cancer. Oxford: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529. Acesso em: 02 jun. 2024. , 2013
APA
Martins, R., Cecotti, H. C., Pierrotti, L. C., Abdala, E., Hoff, P. M. G., & Castro, G. (2013). Risk factors for severe complications during febrile neutropenic episodes in patients with solid tumors: should it be different in elderly? European Journal of Cancer. Oxford: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529
NLM
Martins R, Cecotti HC, Pierrotti LC, Abdala E, Hoff PMG, Castro G. Risk factors for severe complications during febrile neutropenic episodes in patients with solid tumors: should it be different in elderly? [Internet]. European Journal of Cancer. 2013 ; 49 S272.[citado 2024 jun. 02 ] Available from: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529
Vancouver
Martins R, Cecotti HC, Pierrotti LC, Abdala E, Hoff PMG, Castro G. Risk factors for severe complications during febrile neutropenic episodes in patients with solid tumors: should it be different in elderly? [Internet]. European Journal of Cancer. 2013 ; 49 S272.[citado 2024 jun. 02 ] Available from: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529
Artigo de periodico
Percutaneous transhepatic biliary drainage in patients with advanced solid malignancies: Prognostic factors and clinical outcomes (2013)
Teixeira, Marcela Crosara; Mak, Milena Perez; Marques, Daniel Fernandes; Capareli, Fernanda; Carnevale, Francisco Cesar; Moreira, Airton Mota; Ribeiro Jr., Ulysses; Cecconello, Ivan; Hoff, Paulo M.
Source: Journal of Gastrointestinal Cancer. Unidade: FM
Subjects: NEOPLASIAS HEPÁTICAS, DOENÇAS BILIARES, METÁSTASE NEOPLÁSICA, ICTERÍCIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TEIXEIRA, Marcela Crosara et al. Percutaneous transhepatic biliary drainage in patients with advanced solid malignancies: Prognostic factors and clinical outcomes. Journal of Gastrointestinal Cancer, v. 44, n. 4, p. 398-403, 2013Tradução . . Disponível em: http://link.springer.com/article/10.1007%2Fs12029-013-9509-3. Acesso em: 02 jun. 2024.
APA
Teixeira, M. C., Mak, M. P., Marques, D. F., Capareli, F., Carnevale, F. C., Moreira, A. M., et al. (2013). Percutaneous transhepatic biliary drainage in patients with advanced solid malignancies: Prognostic factors and clinical outcomes. Journal of Gastrointestinal Cancer, 44( 4), 398-403. doi:10.1007/s12029-013-9509-3
NLM
Teixeira MC, Mak MP, Marques DF, Capareli F, Carnevale FC, Moreira AM, Ribeiro Jr. U, Cecconello I, Hoff PM. Percutaneous transhepatic biliary drainage in patients with advanced solid malignancies: Prognostic factors and clinical outcomes [Internet]. Journal of Gastrointestinal Cancer. 2013 ; 44( 4): 398-403.[citado 2024 jun. 02 ] Available from: http://link.springer.com/article/10.1007%2Fs12029-013-9509-3
Vancouver
Teixeira MC, Mak MP, Marques DF, Capareli F, Carnevale FC, Moreira AM, Ribeiro Jr. U, Cecconello I, Hoff PM. Percutaneous transhepatic biliary drainage in patients with advanced solid malignancies: Prognostic factors and clinical outcomes [Internet]. Journal of Gastrointestinal Cancer. 2013 ; 44( 4): 398-403.[citado 2024 jun. 02 ] Available from: http://link.springer.com/article/10.1007%2Fs12029-013-9509-3
Trabalho de evento-resumo periodico
Palliative chemotherapy in patients with malignant bowel obstruction (2013)
Muniz, D. Q.; Mak, M. P.; Bitton, R. C.; Takahasi, T. K.; Saragiotto, D. F.; Abdo, E.; Sabbaga, J.; Hoff, Paulo Marcelo Gehm
Source: European Journal of Cancer. Conference titles: European Cancer Congress 2013 Abstract Book. Unidade: FM
Subjects: NEOPLASIAS DO GENITAIS FEMININOS (CIRURGIA;TERAPIA), NEOPLASIAS DO SISTEMA DISGESTÓRIO, TERAPIAS COMPLEMENTARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MUNIZ, D. Q. et al. Palliative chemotherapy in patients with malignant bowel obstruction. European Journal of Cancer. Oxford: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529. Acesso em: 02 jun. 2024. , 2013
APA
Muniz, D. Q., Mak, M. P., Bitton, R. C., Takahasi, T. K., Saragiotto, D. F., Abdo, E., et al. (2013). Palliative chemotherapy in patients with malignant bowel obstruction. European Journal of Cancer. Oxford: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529
NLM
Muniz DQ, Mak MP, Bitton RC, Takahasi TK, Saragiotto DF, Abdo E, Sabbaga J, Hoff PMG. Palliative chemotherapy in patients with malignant bowel obstruction [Internet]. European Journal of Cancer. 2013 ; 49 S281.[citado 2024 jun. 02 ] Available from: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529
Vancouver
Muniz DQ, Mak MP, Bitton RC, Takahasi TK, Saragiotto DF, Abdo E, Sabbaga J, Hoff PMG. Palliative chemotherapy in patients with malignant bowel obstruction [Internet]. European Journal of Cancer. 2013 ; 49 S281.[citado 2024 jun. 02 ] Available from: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529
Trabalho de evento-resumo periodico
Predicting adverse outcomes after cisplatin administration in head & neack and thoracic cancer (2013)
Bitton, R. C.; Castria, T. B.; Amaral, A. A.; Lollo, J. G; Silva, V. T Costa e; Burdmann, Emmanuel de Almeida; Hoff, Paulo Marcelo Gehm; Castro Junior, G.
Source: European Journal of Cancer. Conference titles: European Cancer Congress 2013 Abstract Book. Unidade: FM
Subjects: INSUFICÊNCIA RENAL (ETIOLOGIA), NEOPLASIAS TORÁCICAS (QUIMIOTERAPIA), NEOPLASIAS DE CABEÇA E PESCOÇO (QUIMIOTERAPIA;COMPLICAÇÕES)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BITTON, R. C. et al. Predicting adverse outcomes after cisplatin administration in head & neack and thoracic cancer. European Journal of Cancer. Oxford: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529. Acesso em: 02 jun. 2024. , 2013
APA
Bitton, R. C., Castria, T. B., Amaral, A. A., Lollo, J. G., Silva, V. T. C. e, Burdmann, E. de A., et al. (2013). Predicting adverse outcomes after cisplatin administration in head & neack and thoracic cancer. European Journal of Cancer. Oxford: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529
NLM
Bitton RC, Castria TB, Amaral AA, Lollo JG, Silva VTC e, Burdmann E de A, Hoff PMG, Castro Junior G. Predicting adverse outcomes after cisplatin administration in head & neack and thoracic cancer [Internet]. European Journal of Cancer. 2013 ; 49 S279.[citado 2024 jun. 02 ] Available from: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529
Vancouver
Bitton RC, Castria TB, Amaral AA, Lollo JG, Silva VTC e, Burdmann E de A, Hoff PMG, Castro Junior G. Predicting adverse outcomes after cisplatin administration in head & neack and thoracic cancer [Internet]. European Journal of Cancer. 2013 ; 49 S279.[citado 2024 jun. 02 ] Available from: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529
Trabalho de evento-resumo periodico
Primary thoracic angiosarcoma: treatment and outcomes of 5 patients (2013)
Scaranti, Mariana; Yen, Cheng T.; De Oliveira, Julia A.; Toloi, Diego A.; Siqueira, Sheila A. C.; Martins, Renata E.; De Camargo, Veridiana P.; Feher, Olavo; Hoff, Paulo M.; Castro Jr., Gilberto
Source: Journal of thoracic oncology. Conference titles: World Conference on Lung Cancer. Unidade: FM
Subjects: NEOPLASIAS ABDOMINAIS (TERAPIA;DIAGNÓSTICO), SARCOMA (TERAPIA), PROGNÓSTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SCARANTI, Mariana et al. Primary thoracic angiosarcoma: treatment and outcomes of 5 patients. Journal of thoracic oncology. [S.l.]: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 02 jun. 2024. , 2013
APA
Scaranti, M., Yen, C. T., De Oliveira, J. A., Toloi, D. A., Siqueira, S. A. C., Martins, R. E., et al. (2013). Primary thoracic angiosarcoma: treatment and outcomes of 5 patients. Journal of thoracic oncology. Faculdade de Medicina, Universidade de São Paulo.
NLM
Scaranti M, Yen CT, De Oliveira JA, Toloi DA, Siqueira SAC, Martins RE, De Camargo VP, Feher O, Hoff PM, Castro Jr. G. Primary thoracic angiosarcoma: treatment and outcomes of 5 patients. Journal of thoracic oncology. 2013 ; 8 S1325.[citado 2024 jun. 02 ]
Vancouver
Scaranti M, Yen CT, De Oliveira JA, Toloi DA, Siqueira SAC, Martins RE, De Camargo VP, Feher O, Hoff PM, Castro Jr. G. Primary thoracic angiosarcoma: treatment and outcomes of 5 patients. Journal of thoracic oncology. 2013 ; 8 S1325.[citado 2024 jun. 02 ]
Trabalho de evento-resumo periodico
Liver Irradiation Increases Relapse-Free Survival in Adjuvant Gastric Cancer Treatment (2013)
Vasconcelos, K.; Chen, A. T. C.; Hong, C. B. C.; Nakazato, D.; Stelko, G.; Hoff, P. M. G.; Takeda, F. R.; Zilberstein, B.; Ribeiro Junior, U.; Nadalin, W.
Source: International journal of radiation oncology, biology and physic. Conference titles: Proceedings of the American Society for Radiation Oncology 52nd Annual Meeting, 52nd Annual Meeting of the American Society for Radiation Oncology. Unidade: FM
Subjects: NEOPLASIAS GÁSTRICAS (TERAPIA), PROGNÓSTICO, FÍGADO (PATOLOGIA), METÁSTASE NEOPLÁSICA, NEOPLASIAS HEPÁTICAS, RESUMOS (EVENTOS)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VASCONCELOS, K. et al. Liver Irradiation Increases Relapse-Free Survival in Adjuvant Gastric Cancer Treatment. International journal of radiation oncology, biology and physic. Elmsford: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.ijrobp.2013.06.790. Acesso em: 02 jun. 2024. , 2013
APA
Vasconcelos, K., Chen, A. T. C., Hong, C. B. C., Nakazato, D., Stelko, G., Hoff, P. M. G., et al. (2013). Liver Irradiation Increases Relapse-Free Survival in Adjuvant Gastric Cancer Treatment. International journal of radiation oncology, biology and physic. Elmsford: Faculdade de Medicina, Universidade de São Paulo. doi:10.1016/j.ijrobp.2013.06.790
NLM
Vasconcelos K, Chen ATC, Hong CBC, Nakazato D, Stelko G, Hoff PMG, Takeda FR, Zilberstein B, Ribeiro Junior U, Nadalin W. Liver Irradiation Increases Relapse-Free Survival in Adjuvant Gastric Cancer Treatment [Internet]. International journal of radiation oncology, biology and physic. 2013 ; 87( 2S): S301.[citado 2024 jun. 02 ] Available from: https://doi.org/10.1016/j.ijrobp.2013.06.790
Vancouver
Vasconcelos K, Chen ATC, Hong CBC, Nakazato D, Stelko G, Hoff PMG, Takeda FR, Zilberstein B, Ribeiro Junior U, Nadalin W. Liver Irradiation Increases Relapse-Free Survival in Adjuvant Gastric Cancer Treatment [Internet]. International journal of radiation oncology, biology and physic. 2013 ; 87( 2S): S301.[citado 2024 jun. 02 ] Available from: https://doi.org/10.1016/j.ijrobp.2013.06.790
Trabalho de evento-resumo periodico
Comparison of CKD-EPI, MDRD and Cockcroft-Gault to estimative baseline renal function in patients with head & neck thoracic cancers (2013)
Castria, T. B.; Bitton, R. C.; Amaral, A. A.; Lollo, J. G; Silva, V. T Costa e; Burdmann, Emmanuel de Almeida; Hoff, Paulo Marcelo Gehm; Castro Junior, G.
Source: European Journal of Cancer. Conference titles: European Cancer Congress 2013 Abstract Book. Unidade: FM
Subjects: NEFROPATIAS (ETIOLOGIA), NEOPLASIAS TORÁCICAS (RADIOGRAFIA;COMPLICAÇÕES), NEOPLASIAS DE CABEÇA E PESCOÇO (RADIOTERAPIA)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CASTRIA, T. B. et al. Comparison of CKD-EPI, MDRD and Cockcroft-Gault to estimative baseline renal function in patients with head & neck thoracic cancers. European Journal of Cancer. Oxford: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529. Acesso em: 02 jun. 2024. , 2013
APA
Castria, T. B., Bitton, R. C., Amaral, A. A., Lollo, J. G., Silva, V. T. C. e, Burdmann, E. de A., et al. (2013). Comparison of CKD-EPI, MDRD and Cockcroft-Gault to estimative baseline renal function in patients with head & neck thoracic cancers. European Journal of Cancer. Oxford: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529
NLM
Castria TB, Bitton RC, Amaral AA, Lollo JG, Silva VTC e, Burdmann E de A, Hoff PMG, Castro Junior G. Comparison of CKD-EPI, MDRD and Cockcroft-Gault to estimative baseline renal function in patients with head & neck thoracic cancers [Internet]. European Journal of Cancer. 2013 ; 49 S275.[citado 2024 jun. 02 ] Available from: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529
Vancouver
Castria TB, Bitton RC, Amaral AA, Lollo JG, Silva VTC e, Burdmann E de A, Hoff PMG, Castro Junior G. Comparison of CKD-EPI, MDRD and Cockcroft-Gault to estimative baseline renal function in patients with head & neck thoracic cancers [Internet]. European Journal of Cancer. 2013 ; 49 S275.[citado 2024 jun. 02 ] Available from: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529
Trabalho de evento-resumo periodico
Definitive chemoradiotherapy (CRT) for advanced cancer (CC)0: should it be different in elderly? (2013)
Caires, I. Q. S.; Lima, R. Caires; Souza, R. Barroso; Souza, K. T.; Negrão, M. V.; Carvalho, H.; Abdo Filho, E.; Hoff, Paulo Marcelo Gehm; Diz, M. D. E.P.
Source: European Journal of Cancer. Conference titles: European Cancer Congress 2013 Abstract Book. Unidade: FM
Subjects: IDOSOS, NEOPLASIAS DE CABEÇA E PESCOÇO, ESTUDOS RESTROSPECTIVOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CAIRES, I. Q. S. et al. Definitive chemoradiotherapy (CRT) for advanced cancer (CC)0: should it be different in elderly?. European Journal of Cancer. Oxford: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529. Acesso em: 02 jun. 2024. , 2013
APA
Caires, I. Q. S., Lima, R. C., Souza, R. B., Souza, K. T., Negrão, M. V., Carvalho, H., et al. (2013). Definitive chemoradiotherapy (CRT) for advanced cancer (CC)0: should it be different in elderly? European Journal of Cancer. Oxford: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529
NLM
Caires IQS, Lima RC, Souza RB, Souza KT, Negrão MV, Carvalho H, Abdo Filho E, Hoff PMG, Diz MDEP. Definitive chemoradiotherapy (CRT) for advanced cancer (CC)0: should it be different in elderly? [Internet]. European Journal of Cancer. 2013 ; 49 S722.[citado 2024 jun. 02 ] Available from: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529
Vancouver
Caires IQS, Lima RC, Souza RB, Souza KT, Negrão MV, Carvalho H, Abdo Filho E, Hoff PMG, Diz MDEP. Definitive chemoradiotherapy (CRT) for advanced cancer (CC)0: should it be different in elderly? [Internet]. European Journal of Cancer. 2013 ; 49 S722.[citado 2024 jun. 02 ] Available from: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529
Artigo de periodico
Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors (2013)
Ferrarotto, Renata; Testa, Laura; Riechelmann, Rachel P.; Sahade, Marina; Siqueira, Luiz T.; Costa, Frederico P.; Hoff, Paulo M.
Source: Rare tumors. Unidade: FM
Subjects: NEOPLASIA ENDÓCRINA MÚLTIPLA (TERAPIA), ESTUDOS RETROSPECTIVOS, METÁSTASE NEOPLÁSICA, BIÓPSIA, PROLIFERAÇÃO CELULAR, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FERRAROTTO, Renata et al. Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors. Rare tumors, v. 5, n. 3, p. 121-125, 2013Tradução . . Disponível em: https://doi.org/10.4081/rt.2013.e35. Acesso em: 02 jun. 2024.
APA
Ferrarotto, R., Testa, L., Riechelmann, R. P., Sahade, M., Siqueira, L. T., Costa, F. P., & Hoff, P. M. (2013). Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors. Rare tumors, 5( 3), 121-125. doi:10.4081/rt.2013.e35
NLM
Ferrarotto R, Testa L, Riechelmann RP, Sahade M, Siqueira LT, Costa FP, Hoff PM. Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors [Internet]. Rare tumors. 2013 ; 5( 3): 121-125.[citado 2024 jun. 02 ] Available from: https://doi.org/10.4081/rt.2013.e35
Vancouver
Ferrarotto R, Testa L, Riechelmann RP, Sahade M, Siqueira LT, Costa FP, Hoff PM. Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors [Internet]. Rare tumors. 2013 ; 5( 3): 121-125.[citado 2024 jun. 02 ] Available from: https://doi.org/10.4081/rt.2013.e35
Trabalho de evento-resumo periodico
Lack of association between ERCC1 expression in biliary tract malignancy and response to chemotherapy (2013)
Braghiroli, M.; Dib, L.; Miranda, V.; Siqueira, S.; Hoff, Paulo Marcelo Gehm; Riechelmann, R.
Source: European Journal of Cancer. Conference titles: European Cancer Congress 2013 Abstract Book. Unidade: FM
Subjects: ANTINEOPLÁSICOS, METÁSTASE NEOPLÁSICA, PROGNÓSTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BRAGHIROLI, M. et al. Lack of association between ERCC1 expression in biliary tract malignancy and response to chemotherapy. European Journal of Cancer. Oxford: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529. Acesso em: 02 jun. 2024. , 2013
APA
Braghiroli, M., Dib, L., Miranda, V., Siqueira, S., Hoff, P. M. G., & Riechelmann, R. (2013). Lack of association between ERCC1 expression in biliary tract malignancy and response to chemotherapy. European Journal of Cancer. Oxford: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529
NLM
Braghiroli M, Dib L, Miranda V, Siqueira S, Hoff PMG, Riechelmann R. Lack of association between ERCC1 expression in biliary tract malignancy and response to chemotherapy [Internet]. European Journal of Cancer. 2013 ; 49 S627.[citado 2024 jun. 02 ] Available from: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529
Vancouver
Braghiroli M, Dib L, Miranda V, Siqueira S, Hoff PMG, Riechelmann R. Lack of association between ERCC1 expression in biliary tract malignancy and response to chemotherapy [Internet]. European Journal of Cancer. 2013 ; 49 S627.[citado 2024 jun. 02 ] Available from: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529
Trabalho de evento-resumo periodico
Polymorphisms in the exon 20 of EGFR gene in metastatic lung adenocarcinoma: prognostic relevance and sensitivity to erlotinib (2013)
Castro Jr., Gilberto; Soares, Iberê C.; Takahashi, Tiago K.; Maia, Manuel C. D. F.; Caires-Lima, Rafael; Protasio, Bruno M.; Takagaki, Teresa Y.; Shiang, Christina; Mello, Evandro S.; Hoff, Paulo M.; Alves, Venâncio A.
Source: Journal of thoracic oncology. Conference titles: World Conference on Lung Cancer. Unidade: FM
Subjects: NEOPLASIAS PULMONARES, POLIMORFISMO, ADENOCARCINOMA, TÉCNICAS CITOLÓGICAS (TENDÊNCIAS)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CASTRO JR., Gilberto et al. Polymorphisms in the exon 20 of EGFR gene in metastatic lung adenocarcinoma: prognostic relevance and sensitivity to erlotinib. Journal of thoracic oncology. [S.l.]: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 02 jun. 2024. , 2013
APA
Castro Jr., G., Soares, I. C., Takahashi, T. K., Maia, M. C. D. F., Caires-Lima, R., Protasio, B. M., et al. (2013). Polymorphisms in the exon 20 of EGFR gene in metastatic lung adenocarcinoma: prognostic relevance and sensitivity to erlotinib. Journal of thoracic oncology. Faculdade de Medicina, Universidade de São Paulo.
NLM
Castro Jr. G, Soares IC, Takahashi TK, Maia MCDF, Caires-Lima R, Protasio BM, Takagaki TY, Shiang C, Mello ES, Hoff PM, Alves VA. Polymorphisms in the exon 20 of EGFR gene in metastatic lung adenocarcinoma: prognostic relevance and sensitivity to erlotinib. Journal of thoracic oncology. 2013 ; 8 S784.[citado 2024 jun. 02 ]
Vancouver
Castro Jr. G, Soares IC, Takahashi TK, Maia MCDF, Caires-Lima R, Protasio BM, Takagaki TY, Shiang C, Mello ES, Hoff PM, Alves VA. Polymorphisms in the exon 20 of EGFR gene in metastatic lung adenocarcinoma: prognostic relevance and sensitivity to erlotinib. Journal of thoracic oncology. 2013 ; 8 S784.[citado 2024 jun. 02 ]
Artigo de periodico
KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib (2013)
Smith, John C.; Brooks, Laura; Hoff, Paulo M.; McWalter, Gael; Dearden, Simon; Morgan, Shethah R.; Wilson, David; Robertson, Jane D.; Jürgensmeier, Juliane M.
Source: European Journal of Cancer. Unidade: FM
Subjects: NEOPLASIAS COLORRETAIS (QUIMIOTERAPIA), MUTAÇÃO GENÉTICA, ESTUDOS RETROSPECTIVOS, PROGNÓSTICO, BIOMARCADORES, METÁSTASE NEOPLÁSICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SMITH, John C. et al. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib. European Journal of Cancer, v. 49, n. 10, p. 2424-2432, 2013Tradução . . Disponível em: https://doi.org/10.1016/j.ejca.2013.02.023. Acesso em: 02 jun. 2024.
APA
Smith, J. C., Brooks, L., Hoff, P. M., McWalter, G., Dearden, S., Morgan, S. R., et al. (2013). KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib. European Journal of Cancer, 49( 10), 2424-2432. doi:10.1016/j.ejca.2013.02.023
NLM
Smith JC, Brooks L, Hoff PM, McWalter G, Dearden S, Morgan SR, Wilson D, Robertson JD, Jürgensmeier JM. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib [Internet]. European Journal of Cancer. 2013 ; 49( 10): 2424-2432.[citado 2024 jun. 02 ] Available from: https://doi.org/10.1016/j.ejca.2013.02.023
Vancouver
Smith JC, Brooks L, Hoff PM, McWalter G, Dearden S, Morgan SR, Wilson D, Robertson JD, Jürgensmeier JM. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib [Internet]. European Journal of Cancer. 2013 ; 49( 10): 2424-2432.[citado 2024 jun. 02 ] Available from: https://doi.org/10.1016/j.ejca.2013.02.023
Artigo de periodico
Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas (2013)
Munhoz, Rodrigo Ramella; Rego, Juliana Florinda de Mendonca; Ferrari, Anezka Rubim de Celis; Braghiroli, Maria Ignez; Bariani, Giovanni Mendonca; Hoff, Paulo Marcelo; Costa, Frederico Perego; Pfiffer, Tulio Eduardo Flesch; Riechelmann, Rachel
Source: Rare tumors. Unidade: FM
Subjects: NEOPLASIA ENDÓCRINA MÚLTIPLA, ESTUDOS RETROSPECTIVOS, METÁSTASE NEOPLÁSICA (DIAGNÓSTICO), PROLIFERAÇÃO CELULAR, ANTINEOPLÁSICOS (USO TERAPÊUTICO), CARCINOMA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MUNHOZ, Rodrigo Ramella et al. Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas. Rare tumors, v. 5, n. 3, p. 135-139, 2013Tradução . . Disponível em: https://doi.org/10.4081/rt.2013.e39. Acesso em: 02 jun. 2024.
APA
Munhoz, R. R., Rego, J. F. de M., Ferrari, A. R. de C., Braghiroli, M. I., Bariani, G. M., Hoff, P. M., et al. (2013). Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas. Rare tumors, 5( 3), 135-139. doi:10.4081/rt.2013.e39
NLM
Munhoz RR, Rego JF de M, Ferrari AR de C, Braghiroli MI, Bariani GM, Hoff PM, Costa FP, Pfiffer TEF, Riechelmann R. Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas [Internet]. Rare tumors. 2013 ; 5( 3): 135-139.[citado 2024 jun. 02 ] Available from: https://doi.org/10.4081/rt.2013.e39
Vancouver
Munhoz RR, Rego JF de M, Ferrari AR de C, Braghiroli MI, Bariani GM, Hoff PM, Costa FP, Pfiffer TEF, Riechelmann R. Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas [Internet]. Rare tumors. 2013 ; 5( 3): 135-139.[citado 2024 jun. 02 ] Available from: https://doi.org/10.4081/rt.2013.e39
Trabalho de evento-resumo periodico
Malignancy-related hypercalcemia in the bishosphonate era (2013)
Alves, M. F. S.; Mak, M. P.; Piotto, G. H. M.; Takahasi, T. K.; Ramos, R. E. O; Fonseca, L. G.; Mano, Max Senna; Hoff, Paulo Marcelo Gehm; Castro Junior, G.
Source: European Journal of Cancer. Conference titles: European Cancer Congress 2013 Abstract Book. Unidade: FM
Subjects: CÁLCIO (ANORMALIDADES), NEOPLASIAS DE CABEÇA E PESCOÇO, CARCINOMA DE CÉLULAS ESCAMOSAS, PROGNÓSTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ALVES, M. F. S. et al. Malignancy-related hypercalcemia in the bishosphonate era. European Journal of Cancer. Oxford: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529. Acesso em: 02 jun. 2024. , 2013
APA
Alves, M. F. S., Mak, M. P., Piotto, G. H. M., Takahasi, T. K., Ramos, R. E. O., Fonseca, L. G., et al. (2013). Malignancy-related hypercalcemia in the bishosphonate era. European Journal of Cancer. Oxford: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529
NLM
Alves MFS, Mak MP, Piotto GHM, Takahasi TK, Ramos REO, Fonseca LG, Mano MS, Hoff PMG, Castro Junior G. Malignancy-related hypercalcemia in the bishosphonate era [Internet]. European Journal of Cancer. 2013 ; 49 S288.[citado 2024 jun. 02 ] Available from: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529
Vancouver
Alves MFS, Mak MP, Piotto GHM, Takahasi TK, Ramos REO, Fonseca LG, Mano MS, Hoff PMG, Castro Junior G. Malignancy-related hypercalcemia in the bishosphonate era [Internet]. European Journal of Cancer. 2013 ; 49 S288.[citado 2024 jun. 02 ] Available from: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529
Trabalho de evento-resumo periodico
Should patients with advanced colorectal cancer and ECOG 3/4 be treated with chemotherapy? (2013)
Crosara, M. A. T.; Marques, D. F.; Ferrari, A. C.; Alves, M. F. S.; Alex, A. K.; Sabbaga, J.; Hoff, Paulo Marcelo Gehm; Riechelmann, R.
Source: European Journal of Cancer. Conference titles: European Cancer Congress 2013 Abstract Book. Unidade: FM
Subjects: REGRESSÃO LOGÍSTICA, NEOPLASIAS COLORRETAIS (QUIMIOTERAPIA), PROGNÓSTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CROSARA, M. A. T. et al. Should patients with advanced colorectal cancer and ECOG 3/4 be treated with chemotherapy?. European Journal of Cancer. Oxford: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529. Acesso em: 02 jun. 2024. , 2013
APA
Crosara, M. A. T., Marques, D. F., Ferrari, A. C., Alves, M. F. S., Alex, A. K., Sabbaga, J., et al. (2013). Should patients with advanced colorectal cancer and ECOG 3/4 be treated with chemotherapy? European Journal of Cancer. Oxford: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529
NLM
Crosara MAT, Marques DF, Ferrari AC, Alves MFS, Alex AK, Sabbaga J, Hoff PMG, Riechelmann R. Should patients with advanced colorectal cancer and ECOG 3/4 be treated with chemotherapy? [Internet]. European Journal of Cancer. 2013 ; 49 S288.[citado 2024 jun. 02 ] Available from: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529
Vancouver
Crosara MAT, Marques DF, Ferrari AC, Alves MFS, Alex AK, Sabbaga J, Hoff PMG, Riechelmann R. Should patients with advanced colorectal cancer and ECOG 3/4 be treated with chemotherapy? [Internet]. European Journal of Cancer. 2013 ; 49 S288.[citado 2024 jun. 02 ] Available from: http://ac.els-cdn.com/S0959804913700650/1-s2.0-S0959804913700650-main.pdf?_tid=a8f83b16-6324-11e3-9150-00000aab0f27&acdnat=1386849665_90687616a383bd3e643068fed7140529

USP Schools

ReP

Filtros

USP Schools

Departament

Authors

USP affiliated authors

Date published

Subjects

Source title

Conference titles

Countries/Territories

Funding Agencies

Indexado em

Non normalized affiliation